Trial Profile
A Phase III extension study of efficacy, safety and tolerability of Chronocort in the treatment of congenital adrenal hyperplasia (CAH)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Hydrocortisone (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions; Registrational
- Sponsors Diurnal
- 18 Jun 2023 Results (n=71) of a post-hoc analysis assessing total glucocorticoid daily dose and 9am 17-hydroxyprogesterone levels in MRHC treated patients after 24 months presented at the 105th Annual Meeting of the Endocrine Society
- 15 Jun 2023 Results presented in a Diurnal media release.
- 15 Jun 2023 According to a Diurnal media release, the company will present new post hoc analyses from this study at the ENDO 2023